20230618-华创证券-医药行业跟踪报告_IO+ADC新时代系列二_K药+Padcev有望成为尿路上皮癌一线治疗新标准_9页_1mb

Summary

The report analyzes the potential of combining immunotherapy (IO) with antibody-drug conjugates (ADC) in cancer treatment, with a specific focus on the Kitegast (Keytruda) and Padcev (Enfortumab vedotin) combination for urothelial carcinoma. Key points include:

• IO monotherapies have shown promise but face response rate limitations, making combinations with ADC a promising avenue for improved efficacy. ADCs, as targeted therapies, enhance IO's effectiveness in multiple solid tumors.

• The Kitegast+Padcev combination achieved a high objective response rate (73.3%) and superior progression-free and overall survival in first-line treatment for urothelial carcinoma, outperforming standard platinum-based chemotherapy. This could establish it as a new standard of care, with ongoing head-to-head trials.

• Market opportunities are significant, including potential expansion through combinations like Kitegast+Tecentriq and broader applications in other cancers. China's growing ADC capabilities may position domestic companies for global leadership.

• Risks include uncertainties in clinical trial outcomes, which could delay or invalidate the progress.

Overall, IO+ADC represents a transformative strategy in oncology, with substantial clinical and commercial value potential through enhanced tumor response and treatment duration.